The Motley Fool
25 Jul 2026, 11:11 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
The FDA is expected to issue a decision on the approval of Capricor's treatment, Deramiocel, by August 22. — Regulatory approval is the primary value-driver for clinical-stage biotech companies and can cause massive price swings.
+0.80Capricor Therapeutics has sufficient funding to support operations through the fourth quarter of 2027. — Cash runway reduces the immediate risk of dilutive equity raises for an unprofitable company.
+0.30EVP General Counsel Karen Krasney exercised and sold 24,100 shares for approximately $732,000 via a 10b5-1 trading plan. — While insider selling can be a red flag, a 10b5-1 plan indicates a predetermined schedule rather than a reaction to non-public material information.
-0.10Which stocks this story touches
Continue reading
6 related stories
Search tags
The article discusses an insider sale (neutralized by a 10b5-1 plan) and a mix of year-to-date losses against bullish analyst expectations for an upcoming FDA decision.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Seeking Alpha
8h ago
